JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loscalzo, J.
Right arrow Articles by Cooke, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loscalzo, J.
Right arrow Articles by Cooke, J.

S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets

J Loscalzo, D Smick, N Andon and J Cooke

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

We have synthesized an S-nitrosylated derivative of captopril, S- nitrosocaptopril, that manifests nitrosovasodilatory activity, inhibits angiotensin converting enzyme activity and inhibits platelet aggregation. The direct vasodilatory effects of S-nitrosocaptopril reflect the effects of the thionitrite bond, the presence of which does not in any way influence S-nitrosocaptopril's ability to inhibit angiotensin converting enzyme. Thionitrite stimulation of both vascular and platelet soluble guanylate cyclase activity leads to increases in intracellular cyclic GMP that are accompanied by vasodilatation and platelet inhibition, respectively. S-nitrosocaptopril is a novel hybrid molecule that has potential use in the treatment of hypertension regardless of renin status, angina pectoris and congestive heart failure.

Volume 249, Issue 3, pp. 726-729, 06/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
G. Letts and J. Loscalzo
Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2863 - 2869.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Akhter, A. Vignini, Z. Wen, A. English, P. G. Wang, and B. Mutus
Evidence for S-nitrosothiol-dependent changes in fibrinogen that do not involve transnitrosation or thiolation
PNAS, July 9, 2002; 99(14): 9172 - 9177.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
L. J. Ignarro, C. Napoli, and J. Loscalzo
Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide: An Overview
Circ. Res., January 11, 2002; 90(1): 21 - 28.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Xian, X. Chen, Z. Liu, K. Wang, and P. G. Wang
Inhibition of Papain by S-Nitrosothiols. FORMATION OF MIXED DISULFIDES
J. Biol. Chem., June 30, 2000; 275(27): 20467 - 20473.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics.